



RECEIVED JUL 14 1986

Food and Drug Administration
Rockville MD 20857

Our reference: 62-675

Mutual Pharmaceutical Company, Inc.

Attention: Suhas Sardesai, M.S.

1100 Orthodox Street

Philadelphia, Pennsylvania 19124

JUL 10 1986

Gentlemen:

Please refer to your Abbreviated Antibiotic Drug Application for Doxycycline Hyclate Capsules, U.S.P., 50 mg.

Please also refer to your submissions dated January 28 and March 10, 1986.

We have completed our review of the application and it is approved.

An expiration date of twenty-four (24) months should be used on each batch of the drug to be marketed and packaged as described in the application.

Place drug samples from the first three production batches into your stability program and test each batch at three (3) month intervals during the first year of aging, at six (6) month intervals during the second year, annually thereafter. As the data become available they should be furnished to this office at six (6) month intervals throughout the authorized shelf life of the subject drug.

For Initial Campaigns: We request that you submit, in duplicate, any proposed advertising or promotional copy which you intend to use in your immediate advertising or promotional campaigns. Please submit all proposed materials in draft or mock-up form, not final printed. Submit both copies together with a copy of the proposed or final printed labeling to the Division of Drug Advertising and Labeling (HFN-240). Also, please do not use Form FD-2253 for this submission.

For Subsequent Campaigns: We call your attention to regulation 21 CFR 314.81(b)(3) which requires that all material for any subsequent advertising or promotional campaigns at the time of their initial use be submitted to our Division of Drug Advertising and Labeling (HFN-240) with a completed Form FD-2253. A copy of Form FD-2253 is enclosed for your convenience.


Please be reminded that since you are manufacturing the subject drug for the first time, that 21 CFR 314.81 requires that certain records and reports be submitted following the date of marketing of a batch at three (3) month intervals during the first year, at six (6) month intervals during the second year, and annually thereafter.

62-675

page 2

The application should be kept up to date by submitting supplements whenever changes are contemplated in the manufacturing and/or laboratory procedures, controls, equipment and instrumentation, key scientific and production personnel, packaging, labeling, source of antibiotic, etc.

Sincerely yours,

A handwritten signature in black ink, reading "Marvin Seife". The signature is fluid and cursive, with a large initial "M" and a long, sweeping underline.

Marvin Seife, M.D.

Director

Division of Generic Drugs

Office of Drug Standards

Center for Drugs and Biologics

Enclosure